

PE/Cyanine7 anti-mouse CD11c Antibody

Catalog# / Size	117317 / 25 µg 117318 / 100 µg
Clone	N418
Regulatory Status	RUO
Other Names	αX integrin, integrin αX chain, CR4, p150, ITGAX
Isotype	Armenian Hamster IgG
Description	CD11c is a 150 kD glycoprotein also known as αX integrin, CR4, and p150. CD11c forms a αXβ2 heterodimer with β2 integrin (CD18). It is primarily expressed on dendritic cells, NK cells, a subset of intestinal intraepithelial lymphocytes (IEL), and some activated T cells. The αXβ2 integrin plays an important role in cell-cell contact by binding its ligands: iC3b, fibrinogen, and CD54.

Product Details

Verified Reactivity	Mouse
Antibody Type	Monoclonal
Host Species	Armenian Hamster
Immunogen	Mouse spleen dendritic cells
Formulation	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation	The antibody was purified by affinity chromatography, and conjugated with PE/Cyanine7 under optimal conditions.
Concentration	0.2 mg/ml
Storage & Handling	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application	FC - Quality tested
Recommended Usage	Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis . For flow cytometric staining, the suggested use of this reagent is = 0.25 µg per 10 ⁶ cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for other applications.
Excitation Laser	Blue Laser (488 nm) Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes	Additional reported applications (for the relevant formats) include: immunoprecipitation ³ , immunohistochemical staining of acetone-fixed frozen sections ³ , immunofluorescence microscopy ^{5,9} (Alexa Fluor® 488 conjugated N418 was used for IHC in frozen sections ¹⁰), and spatial biology (IBEX) ^{22,23} .
Additional Product Notes	View more applications data for this product in our Scientific Poster Library .
	BioLegend is in the process of converting the name PE/Cy7 to PE/Cyanine7. The dye molecule remains the same, so you should expect the same quality and performance from our PE/Cyanine7 products. Please contact Technical Service if you have any questions.

Application References

(PubMed link indicates BioLegend citation)

1. Granucci F, *et al.* 1997. *J. Immunol.* 159:1794.
2. Stokes RW, *et al.* 1998. *J. Immunol.* 160:5514.
3. Metlay JP, *et al.* 1990. *J. Exp. Med.* 171:1753. (IHC, IP)
4. Ma XT, *et al.* 2006. *Cancer Research* 66:1169.
5. Chin RK, *et al.* 2006. *J. Immunol.* 177:290. (IF)

6. Cervantes-Barragan L, et al. 2007. *Blood* 109:1131. (FC) [PubMed](#)
7. Turnquist HR, et al. 2007. *J. Immunol.* 178:7018. (FC) [PubMed](#)
8. Benson MJ, et al. 2007. *J. Exp. Med.* doi:10.1084/jem.20070719. (FC) [PubMed](#)
9. You Y, et al. 2009. *J. Immunol.* 182:7343. (IF) [PubMed](#)
10. Roland CL, et al. 2009. *Mol. Cancer Res.* 8:1761. (IHC, FC) [PubMed](#)
11. Wikstrom M, et al. 2006. *J. Immunol.* 177:913. [PubMed](#)
12. Pericolini E, et al. 2008. *J. Leukocyte Biol.* 83:1286. [PubMed](#)
13. Randall LM, et al. 2008. *Infect. Immun.* 76:3312. [PubMed](#)
14. Fahlen-Yrild L, et al. 2009. *J. Immunol.* 183:5032. [PubMed](#)
15. Osterholzer JJ, et al. 2009. *J. Immunol.* 183:8044. [PubMed](#)
16. Bankoti J, et al. 2010. *Toxicol. Sci.* 115:422. (FC) [PubMed](#)
17. Eisenach PA, et al. 2010. *J Cell Sci.* 123:4182. [PubMed](#)
18. Leppin K, et al. 2014. *Invest. Ophthalmol. Vis. Sci.* 55:3603. [PubMed](#)
19. Sakai F, et al. 2014. *PLoS One.* 9:105370. [PubMed](#)
20. Gibbins JD, et al. 2014. *Blood.* 124:2953. [PubMed](#)
21. White CE, et al. 2015. *J Immunol.* 194:697. [PubMed](#)
22. Lu X, et al. 2015. *J Immunol.* 194:2011. [PubMed](#)
23. Radtke AJ, et al. 2020. *Proc Natl Acad Sci U S A.* 117:33455-65. (SB) [PubMed](#)
24. Radtke AJ, et al. 2022. *Nat Protoc.* 17:378-401. (SB) [PubMed](#)

Product Citations

1. Liu Y, et al. 2021. *Cell Metabolism.* 33(6):1221-1233.e11. [PubMed](#)
2. Sun L, et al. 2021. *Cancer Cell.* .: [PubMed](#)
3. Komuczki J, et al. 2019. *Immunity.* 50:1289. [PubMed](#)
4. Wang X, et al. 2019. *Cell Res.* 29:787. [PubMed](#)
5. Kimura S, et al. 2020. *Nat Commun.* 0.620833333. [PubMed](#)
6. Al-Rashed F, et al. 2020. *Sci Rep.* 10:16802. [PubMed](#)
7. Jiang Z, et al. 2021. *J Clin Invest.* 131: . [PubMed](#)
8. Zhou R, et al. 2022. *EBioMedicine.* 75:103762. [PubMed](#)
9. Friess MC, et al. 2022. *Cell Rep.* 38:110334. [PubMed](#)
10. Hutter K, et al. 2022. *Front Immunol.* 13:967914. [PubMed](#)
11. Furrer R, et al. 2021. *Sci Adv.* 7:eabi4852. [PubMed](#)
12. Wiesner DL, et al. 2020. *Cell Host Microbe.* 614:27. [PubMed](#)
13. Furuta Y, et al. 2017. *PLoS One.* 12(2):e0172509. [PubMed](#)
14. Kolawole A, et al. 2015. *J Virol.* 90: 1499-1506. [PubMed](#)
15. Kawano H, et al. 2016. *Int Immunol.* 28: 489 - 501. [PubMed](#)
16. Shin J, et al. 2016. *Sci Rep.* 6:23426. [PubMed](#)
17. Fu R, et al. 2020. *Sci Rep.* 10:1455. [PubMed](#)
18. Fachi JL, et al. 2019. *Cell reports.* 27(3):750-761. [PubMed](#)
19. Hastings AK, et al. 2019. *iScience.* 13:339. [PubMed](#)
20. Lyons J, et al. 2018. *PLoS Biol.* 16:e2002417. [PubMed](#)
21. van Vloten JP, et al. 2022. *J Immunother Cancer.* 10:.. [PubMed](#)
22. Ferrere G, et al. 2021. *JCI Insight.* 6:.. [PubMed](#)
23. Jong RM, et al. 2022. *J Immunol.* 208:407. [PubMed](#)
24. Ercoli G, et al. 2021. *Front Immunol.* 11:611661. [PubMed](#)
25. Suzuki T, et al. 2014. *J Dermatol Sci.* 74:116. [PubMed](#)
26. Clark K, et al. 2015. *J Autoimmun.* Available online 21 August 2015. [PubMed](#)
27. Ndoja A, et al. 2020. *Cell.* 182(5):1156-1169.e12. [PubMed](#)
28. Dong L, et al. 2021. *Cancer Cell.* . [PubMed](#)
29. Yu K, et al. 2021. *Cell Reports.* 35(12):109273. [PubMed](#)
30. Clarke F, et al. 2017. *PLoS One.* 10.1371/journal.pone.0186625. [PubMed](#)
31. Thwe PM, et al. 2017. *Cell metabolism.* 26(3):558-567. [PubMed](#)
32. Kurelac I, et al. 2019. *Nat Commun.* 10:903. [PubMed](#)
33. Quatrini L, et al. 2018. *Nat Immunol.* 19:954. [PubMed](#)
34. Shen Y, et al. 2021. *Comput Struct Biotechnol J.* 19:5360. [PubMed](#)
35. Chen L, et al. 2022. *Mol Ther Oncolytics.* 24:522. [PubMed](#)
36. Boldison J, et al. 2020. *Cell Mol Immunol.* 17:843. [PubMed](#)
37. Liang S, et al. 2022. *Acta Pharm Sin B.* 12:2494. [PubMed](#)
38. Pack AD, et al. 2021. *Cell Reports.* 36(8):109586. [PubMed](#)
39. Hearnden R, et al. 2021. *STAR Protocols.* 2(2):100422. [PubMed](#)
40. Yousif AS, et al. 2020. *Immunity.* 54(2):235-246.e5. [PubMed](#)
41. Ku M, et al. 2016. *Mol Cancer Ther.* 15: 1975 - 1987. [PubMed](#)
42. Wong E, et al. 2019. *Cell Rep.* 29:3047. [PubMed](#)
43. Yuzhu Hou, et al. 2018. *Immunity.* 49(3):490-503. [PubMed](#)
44. Castellanos CA, et al. 2021. *Sci Immunol.* 6:eabh0707. [PubMed](#)
45. Rao E, et al. 2021. *Sci Immunol.* 6:.. [PubMed](#)
46. Tilstam PV, et al. 2021. *J Clin Invest.* 131:.. [PubMed](#)
47. Yu X, et al. 2021. *Nature.* 594:560. [PubMed](#)
48. Morgado P, et al. 2014. *Infect Immun.* 82:4047. [PubMed](#)
49. Ohtsuki T, et al. 2016. *J Virol.* 90: 300 - 307. [PubMed](#)
50. Bazett M, Haston M 2016. *Sci Rep.* 6:19189. [PubMed](#)
51. Rao S, et al. 2017. *Cell.* 168(3):503-516.e12. [PubMed](#)
52. Si Y, et al. 2020. *Sci Adv.* 6:eaba0995. [PubMed](#)
53. Evren E, et al. 2020. *Immunity.* 54(2):259-275.e7. [PubMed](#)
54. Schiller M, et al. 2021. *Immunity.* 54(5):1022-1036.e8. [PubMed](#)
55. Jtte BB, et al. 2021. *iScience.* 24(8):102833. [PubMed](#)
56. Bartleson JM, et al. 2020. *Nat Immunol.* 1384:21. [PubMed](#)
57. Dave K, et al. 2017. *eLife.* 6 pii: e23382. [PubMed](#)
58. Go DM, et al. 2021. *Cell Mol Gastroenterol Hepatol.* 12:715. [PubMed](#)

59. Papafragkos I, *et al.* 2022. *Front Immunol.* 13:889075. [PubMed](#)
60. Moreau GB, *et al.* 2020. *Am J Trop Med Hyg.* 103:1215. [PubMed](#)
61. van Dierendonck XAMH, *et al.* 2020. *Cell Reports.* 30(6):1811-1822. [PubMed](#)
62. Nguyen CM, *et al.* 2019. *Diabetes.* 68:1499. [PubMed](#)
63. Britton GJ *et al.* 2019. *Immunity.* 50(1):212-224. [PubMed](#)
64. Lyons J, *et al.* 2018. *Sci Signal.* 11. [PubMed](#)
65. Khan IM, *et al.* 2021. *Immunohorizons.* 5:703. [PubMed](#)
66. Zhang J, *et al.* 2022. *Front Immunol.* 13:931740. [PubMed](#)
67. Zhang C, *et al.* 2021. *Clin Transl Immunology.* 10:e1310. [PubMed](#)
68. Francian A, *et al.* 2021. *J Drug Target.* 29:754. [PubMed](#)
69. Sato Y, *et al.* 2021. *J Clin Invest.* Online ahead of print. [PubMed](#)
70. Bagayoko S, *et al.* 2021. *PLoS Pathog.* 17:e1009927. [PubMed](#)
71. Cousin N, *et al.* 2021. *Cancer Res.* 81:4133. [PubMed](#)
72. Škrnjug I, *et al.* 2014. *PLoS One.* 9:110150. [PubMed](#)
73. Lee M, *et al.* 2014. *PLoS One.* 9:112666. [PubMed](#)
74. Syed A, *et al.* 2015. *Infect Immun.* 83: 3428-3437. [PubMed](#)
75. Zhang Y, *et al.* 2015. *PLoS Pathog.* 11: e1005167. [PubMed](#)
76. Ben-Shaan T, *et al.* 2016. *Nat Med.* 10.1038/nm.4133. [PubMed](#)
77. Koren N, *et al.* 2021. *Cell Host Microbe.* 29(2):197-209.e5. [PubMed](#)
78. An J, *et al.* 2017. *Sci Rep.* 10.1038/s41598-017-13629-0. [PubMed](#)
79. Emgård J, *et al.* 2018. *Immunity.* 143:419. [PubMed](#)
80. Koliaraki V *et al.* 2019. *Cell reports.* 26(3):536-545. [PubMed](#)
81. Perry JSA, *et al.* 2018. *Immunity.* 48:923. [PubMed](#)
82. Zeng J, *et al.* 2019. *Cell Rep.* 27:549. [PubMed](#)
83. Davidson S, *et al.* 2020. *Cell Reports.* 31(7):107628. [PubMed](#)
84. Wu X, *et al.* 2021. *Elife.* 10:. [PubMed](#)
85. Crosse EI, *et al.* 2020. *Cell Stem Cell.* 27:822. [PubMed](#)
86. Sellau J, *et al.* 2016. *Sci Rep.* 6:28058. [PubMed](#)
87. Rosen D, *et al.* 2016. *J Infect Dis.* 213: 649 - 658. [PubMed](#)
88. Kelsey E Sivick *et al.* 2018. *Cell reports.* 25(11):3074-3085. [PubMed](#)
89. Fatkhullina AR *et al.* 2018. *Immunity.* 49(5):943-957. [PubMed](#)
90. Novkovic M, *et al.* 2016. *PLoS Biol.* 14: 1002515. [PubMed](#)
91. He Y, *et al.* 2021. *Cell Metabolism.* 33(5):988-1000.e7. [PubMed](#)
92. Souza COS, *et al.* 2021. *iScience.* 24(6):102548. [PubMed](#)
93. Connick K, *et al.* 2020. *J Parasit Dis.* 186:44. [PubMed](#)
94. Johnson LA, *et al.* 2021. *Life Sci Alliance.* :4. [PubMed](#)
95. Deng M, *et al.* 2020. *Nat Commun.* 11:2193. [PubMed](#)
96. Si Y, *et al.* 2018. *J Control Release.* 282:120. [PubMed](#)
97. Baudoux T, *et al.* 2018. *Sci Rep.* 4.0375. [PubMed](#)
98. Russler-Germain EV, *et al.* 2021. *Elife.* 10:. [PubMed](#)
99. Pan Y, *et al.* 2022. *J Clin Invest.* 132:. [PubMed](#)
100. Harb H, *et al.* 2021. *Immunity.* 54(6):1186-1199.e7. [PubMed](#)
101. Tacconi C, *et al.* 2021. *Cell Reports.* 35(2):108993. [PubMed](#)
102. Dieterich LC, *et al.* 2020. *Angiogenesis.* 1.24375. [PubMed](#)
103. Vettorazzi S, *et al.* 2015. *Nat Commun.* 6: 7796. [PubMed](#)
104. Christ A, *et al.* 2018. *Cell.* 172:162. [PubMed](#)
105. Calcinotto A, *et al.* 2018. *Nat Commun.* 9:4832. [PubMed](#)
106. Habib S, *et al.* 2018. *Infect Immun.* 86:e00019. [PubMed](#)
107. Krollmann C, *et al.* 2022. *STAR Protoc.* 3:101309. [PubMed](#)
108. Harnett MM, *et al.* 2022. *Front Immunol.* 13:953053. [PubMed](#)
109. , *et al.* 2021. *Eur J Immunol.* 51:2708. [PubMed](#)
110. Ercoli G, *et al.* 2022. *Clin Transl Immunology.* 11:e1366. [PubMed](#)
111. Lewis EL, *et al.* 2021. *Front Immunol.* 12:741518. [PubMed](#)
112. Panea C, *et al.* 2021. *Commun Biol.* 4:913. [PubMed](#)
113. Gibbins J, *et al.* 2014. *Blood.* 124:2953. [PubMed](#)
114. Schaefer K, *et al.* 2014. *PLoS One.* 9:114824. [PubMed](#)
115. Engler AE, *et al.* 2020. *Cell Reports.* 33(13):108553. [PubMed](#)
116. Kim SH, *et al.* 2021. *Cell Reports.* 35(2):108995. [PubMed](#)
117. Moon HG *et al.* 2018. *Immunity.* 49(2):275-287. [PubMed](#)
118. Hiebert P *et al.* 2018. *Developmental cell.* 46(2):145-161. [PubMed](#)
119. Tran NT, *et al.* 2020. *STAR Protocols.* 1(1):100028. [PubMed](#)
120. Liu S, *et al.* 2020. *Cell Host & Microbe.* 26(6):779-794.e8.. [PubMed](#)
121. Liang J, *et al.* 2020. *Sci Adv.* 6:eabc3646. [PubMed](#)
122. Nikolos F, *et al.* 2022. *Nat Commun.* 13:1487. [PubMed](#)
123. Colombo M, *et al.* 2022. *iScience.* 25:105042. [PubMed](#)
124. Reimer E, *et al.* 2020. *J Cell Sci.* 134:00:00. [PubMed](#)
125. Cuenca M, *et al.* 2016. *J Immunol.* 196: 726 - 737. [PubMed](#)
126. Hayashi K, *et al.* 2015. *Int Immunol.* 27: 435-445. [PubMed](#)
127. Ermert D, *et al.* 2016. *PLoS Pathog.* 11: 1005043. [PubMed](#)
128. Choi EW, *et al.* 2020. *Sci Rep.* 10:12001. [PubMed](#)
129. Yang C, *et al.* 2019. *Nanomedicine (Lond).* 14:2423. [PubMed](#)
130. Janela B, *et al.* 2019. *Immunity.* 50:1069. [PubMed](#)
131. Puigdelloses M, *et al.* 2021. *J Immunother Cancer.* 9:. [PubMed](#)
132. Daneshmandi S, *et al.* 2021. *Elife.* 10:. [PubMed](#)
133. Henrich IC, *et al.* 2021. *Cancer Res.* 81:2171. [PubMed](#)
134. Monaghan KL, *et al.* 2020. *J Vis Exp.* . [PubMed](#)
135. Colliou N, *et al.* 2015. *Toxins.* 7: 3805 - 3817. [PubMed](#)
136. Shepardson K, *et al.* 2016. *MBio.* 7: e00506-16. [PubMed](#)
137. Wei Z, *et al.* 2021. *Nat Commun.* 0.805555556. [PubMed](#)
138. Lan H, *et al.* 2020. *Int Immunol.* 559:32. [PubMed](#)

139. Taddio MF, *et al.* 2021. Mol Imaging Biol. 23:196. [PubMed](#)
140. Zhang X, *et al.* 2021. Mol Cancer Res. 19:1076. [PubMed](#)
141. Yang X, *et al.* 2022. Front Immunol. 13:856230. [PubMed](#)
142. Hirata SI, *et al.* 2020. Allergy. 75:1939. [PubMed](#)
143. Morikawa M, *et al.* 2016. PLoS One. 11:e0163607. [PubMed](#)
144. Kim M, *et al.* 2018. Immunity. 49:151. [PubMed](#)
145. Lu Y, *et al.* 2020. Immunity. 52:782. [PubMed](#)
146. Dahlgren MW *et al.* 2019. Immunity. 50(3):707-722 . [PubMed](#)
147. Xueyang Yu *et al.* 2017. Immunity. 47(5):903-912 . [PubMed](#)
148. Nagatake T, *et al.* 2018. J Allergy Clin Immunol. 142:470. [PubMed](#)
149. Zwick M, *et al.* 2019. Front Immunol. 10:222. [PubMed](#)
150. Chan WY, *et al.* 2019. Infect Immun. 87:. [PubMed](#)
151. Ghorbani S, *et al.* 2022. Nat Commun. 13:2445. [PubMed](#)
152. Clement CC, *et al.* 2021. Immunity. 54:721. [PubMed](#)
153. Hennion-Tscheltzoff O, *et al.* 2013. Blood. 121:4684. [PubMed](#)
154. Škrnjug I, *et al.* 2014. PLoS One. 9:95728. [PubMed](#)
155. Velázquez F, *et al.* 2016. J Immunol. 196: 1305 - 1316. [PubMed](#)
156. Ghosh D, *et al.* 2016. J Immunol. 197: 1788 - 1800. [PubMed](#)
157. Yasuda T, *et al.* 2016. PLoS One. 11:e0167952. [PubMed](#)
158. Kumari P, *et al.* 2021. Cell Reports. 35(3):109012. [PubMed](#)
159. Liu P, *et al.* 2020. Mol Cell. 74:77. [PubMed](#)
160. Andersen TK, *et al.* 2019. NPJ Vaccines. 4:9. [PubMed](#)
161. Lai SM *et al.* 2018. Cell reports. 25(11):3099-3109 . [PubMed](#)
162. Urata S, *et al.* 2018. PLoS Pathog. 14:e1007172. [PubMed](#)
163. Zhao Y, *et al.* 2020. Immunity. 51(6):1059-1073.e9.. [PubMed](#)
164. Li E, *et al.* 2021. Front Immunol. 12:667177. [PubMed](#)
165. He S, *et al.* 2021. Front Pharmacol. 12:743837. [PubMed](#)
166. Wang L, *et al.* 2021. Sci Adv. 7:eabj4796. [PubMed](#)
167. Walker MT, *et al.* 2021. Front. Allergy. 2:. [PubMed](#)
168. Harb H, *et al.* 2020. Nat Immunol. 21:1359-21. [PubMed](#)
169. Niven J, *et al.* 2019. Cell Rep. 28:21. [PubMed](#)
170. Clemente-Casares X, *et al.* 2017. Immunity. 47:974. [PubMed](#)
171. Leary N, *et al.* 2022. J Extracell Vesicles. 11:e12197. [PubMed](#)
172. Xu W, *et al.* 2021. Immunity. 54(3):526-541.e7. [PubMed](#)
173. Di Pilato M, *et al.* 2021. Cell. 184(17):4512-4530.e22. [PubMed](#)
174. Chung S, *et al.* 2020. Am J Physiol Lung Cell Mol Physiol. L921:318. [PubMed](#)
175. Stefan KL, *et al.* 2020. Cell. 1312:183. [PubMed](#)
176. Porrello A, *et al.* 2018. Nat Commun. 9:1988. [PubMed](#)
177. Ding L *et al.* 2018. Cell reports. 25(11):2972-2980 . [PubMed](#)
178. Meng Michelle Xu *et al.* 2017. Immunity. 47(2):363-373 . [PubMed](#)
179. Yoshida H, *et al.* 2019. Cell. 176:897. [PubMed](#)
180. Donlan AN, *et al.* 2021. JCI Insight. 6: . [PubMed](#)
181. Okreglicka K, *et al.* 2021. J Exp Med. 218:. [PubMed](#)
182. Van Nuffel E, *et al.* 2020. EMBO Rep. 21:e49237. [PubMed](#)
183. Liu SS, *et al.* 2021. Immunity. .: [PubMed](#)
184. Xu C, *et al.* 2021. Cell Reports. 35(11):109235. [PubMed](#)
185. Hildreth AD, *et al.* 2020. STAR Protoc. 1:100113. [PubMed](#)
186. Rosnagl S, *et al.* 2016. PLoS Biol. 14: 1002562. [PubMed](#)
187. Wan X, Thomas J, Unanue E 2016. J Exp Med. 213: 967 - 978. [PubMed](#)
188. Yu H, *et al.* 2015. PLoS One. 10: 0143001. [PubMed](#)
189. Jin J, *et al.* 2020. Cell Reports. 30(12):4124-4136. [PubMed](#)
190. Schuh E, *et al.* 2017. J Immunol. 198:3081. [PubMed](#)
191. Tippimanchai DD, *et al.* 2018. Oncoimmunology. 7:e1438105. [PubMed](#)
192. Stotesbury C, *et al.* 2020. Aging Cell. 19:e13170. [PubMed](#)
193. Teng F, *et al.* 2021. Cell Rep. 37:110051. [PubMed](#)
194. Ceglia V, *et al.* 2021. J Immunol. 207:2060. [PubMed](#)
195. Bahmani B, *et al.* 2021. Nat Commun. 12:1999. [PubMed](#)
196. Fite BZ, *et al.* 2021. Sci Rep. 11:927. [PubMed](#)
197. Lee HN, *et al.* 2022. JCI Insight. 7:. [PubMed](#)
198. Verma M, *et al.* 2021. J Exp Med. 218:. [PubMed](#)
199. Kim J, *et al.* 2020. Adv Funct Mater. 30:. [PubMed](#)
200. Lee GR, *et al.* 2021. JCI Insight. 6:. [PubMed](#)
201. Stack G, *et al.* 2015. PLoS Pathog. 11:1004641. [PubMed](#)
202. Tran S, *et al.* 2020. Immunity. 53(3):627-640.e5. [PubMed](#)
203. Goc J, *et al.* 2021. Cell. .: [PubMed](#)
204. Wunderlich CM, *et al.* 2018. Nat Commun. 9:1646. [PubMed](#)
205. Albaghdadi AJH, *et al.* 2019. Sci Rep. 9:6528. [PubMed](#)
206. Ioanna E Galani *et al.* 2017. Immunity. 46(5):875-890 . [PubMed](#)
207. Crowe J, *et al.* 2020. PLoS Pathog. 16:e1008391. [PubMed](#)
208. Saleh R, *et al.* 2018. J Immunol. 201:2042. [PubMed](#)
209. Doo DW, *et al.* 2020. Ther Adv Med Oncol. 12:1758835920913798. [PubMed](#)
210. Schäfer AL, *et al.* 2021. Front Immunol. 12:696810. [PubMed](#)
211. Hsu HP, *et al.* 2021. J Biol Chem. 296:100419. [PubMed](#)
212. Rivera CA, *et al.* 2022. Immunity. 55:129. [PubMed](#)
213. Dietschmann A, *et al.* 2020. Eur J Immunol. 50:1044. [PubMed](#)
214. Dai B, *et al.* 2021. Cell Reports Medicine. 2(8):100381. [PubMed](#)
215. Trivedi S, *et al.* 2020. Elife. 9:00. [PubMed](#)
216. Hayashi K, *et al.* 2020. Nat Commun. 11:4832638889. [PubMed](#)
217. Fontana C, *et al.* 2016. J Biol Chem. 291: 7727-7741. [PubMed](#)
218. Uematsu T, *et al.* 2015. Sci Rep. 5: 17577. [PubMed](#)

219. Thomson CA, *et al.* 2018. J Immunol. 201:215. [PubMed](#)
 220. Chen S, *et al.* 2018. Nat Commun. 9:5298. [PubMed](#)
 221. Zhang Y, *et al.* 2022. J Immunother Cancer. 10:. [PubMed](#)
 222. Lee S, *et al.* 2021. Autophagy. Online ahead of print. [PubMed](#)
 223. Amend A, *et al.* 2021. Int J Mol Sci. 22:. [PubMed](#)
 224. Wirasinha RC, *et al.* 2021. J Exp Med. 218: . [PubMed](#)

RRID AB_493569 (BioLegend Cat. No. 117317)
 AB_493568 (BioLegend Cat. No. 117318)

Antigen Details

Structure	Integrin α -chain, associates with integrin β_2 (CD18), 150 kD
Distribution	Dendritic cells, NK cells, intestinal intraepithelial lymphocytes (IEL), some activated T cells
Function	Cellular adhesion
Ligand/Receptor	iC3b, fibrinogen
Cell Type	Dendritic cells, Epithelial cells, NK cells, T cells, Tregs
Biology Area	Cell Adhesion, Cell Biology, Costimulatory Molecules, Immunology, Innate Immunity, Neuroscience, Neuroscience Cell Markers
Molecular Family	Adhesion Molecules, CD Molecules
Antigen References	1. Barclay A, <i>et al.</i> 1997. The Leukocyte Antigen Facts Book Academic Press. 2. Springer TA. 1994. <i>Cell</i> 76:301. 3. Lopez-Rodriguez C, <i>et al.</i> 1996. <i>J. Immunol.</i> 156:3780.
Gene ID	16411


Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)


Other Formats

APC anti-mouse CD11c, Biotin anti-mouse CD11c, FITC anti-mouse CD11c, PE anti-mouse CD11c, Purified anti-mouse CD11c, Alexa Fluor® 488 anti-mouse CD11c, Alexa Fluor® 647 anti-mouse CD11c, PE/Cyanine5 anti-mouse CD11c, PE/Cyanine7 anti-mouse CD11c, Brilliant Violet 605™ anti-mouse CD11c, Alexa Fluor® 700 anti-mouse CD11c, Pacific Blue™ anti-mouse CD11c, APC/Cyanine7 anti-mouse CD11c, PerCP/Cyanine5.5 anti-mouse CD11c, PerCP anti-mouse CD11c, Brilliant Violet 421™ anti-mouse CD11c, Brilliant Violet 570™ anti-mouse CD11c, Brilliant Violet 785™ anti-mouse CD11c, Brilliant Violet 510™ anti-mouse CD11c, Brilliant Violet 650™ anti-mouse CD11c, Purified anti-mouse CD11c (Maxpar® Ready), Alexa Fluor® 594 anti-mouse CD11c, PE/Dazzle™ 594 anti-mouse CD11c, Brilliant Violet 711™ anti-mouse CD11c, APC/Fire™ 750 anti-mouse CD11c, TotalSeq™-A0106 anti-mouse CD11c, Brilliant Violet 750™ anti-mouse CD11c, TotalSeq™-B0106 anti-mouse CD11c, TotalSeq™-C0106 anti-mouse CD11c, KIRAVIA Blue 520™ anti-mouse CD11c, Spark Blue™ 550 anti-mouse CD11c, Spark NIR™ 685 anti-mouse CD11c, Spark UV™ 387 anti-mouse CD11c, Spark Red™ 718 anti-mouse CD11c

Product Data



C57BL/6 mouse splenocytes stained with APC anti-mouse I-A/I-E (clone M5/114.15.2) and PE/Cyanine7 N418 (top) or PE/Cyanine7 Armenian hamster IgG isotype control (bottom)



For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587